Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 7, 2010Headache The Journal of Head and Face Pain

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program

View Full Paper
Ask AI
Bookmark
Share

Authors

DDDavid W. DodickDartmouth CollegeCTCatherine C. TurkelPhusis Therapeutics (United States)RDRonald E. DeGryseAbbVie (United States)

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Dodick et al. (2010) studied this question.

synapsesocial.com/papers/69df3e0b35659245ec6143dehttps://doi.org/10.1111/j.1526-4610.2010.01678.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Migraine Prophylactic Medication Usage Patterns in the Netherlands2003 · 39 citations
  2. 2Mouse bioassay versus Western blot assay for botulinurn toxin antibodies Correlation with clinical response1998 · 115 citations
  3. 3Clinical Comparisons of Botulinum Neurotoxin Formulations2008 · 40 citations
  4. 4Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies1999 · 79 citations
  5. 5Botulinum Toxin Type A in the Treatment of Chronic Migraine Without Medication Overuse2007 · 119 citations